The 4Cs every CDMO vendor should know

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Carl Turner, Vice President Supply Chain at Mayne Pharma. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Carl, covering: Managing 30+ CDMOs across several drug delivery systems and having the unique perspective of being on the buy CMO side, but having visibility of the CMO sell side. The 4 Cs that Carl looks for in sourcing, evaluating and selecting a new CMO partner. And what a great vendor relationship looks like The constant balancing act of risk mitigation and achieving economies of scale in using third party vendors. The impact of globalisation on product supply and the value of having plant-level contacts and communications. Carl has almost three decades of experience in the pharmaceutical sector. A biologist by trade, he worked his way up the ranks at Abbot for 12 years in operations. He then made his way into planning and supply chain operations during 11 years with Hospira (became Pfizer). He has spent the rest of his career at Mayne Pharma helping the Australian-headquartered pharma company manage its complicated clinical and commercial global supply chain. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.